Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to crack the code of autoimmune diseases

NCT ID NCT04902807

Recruiting now Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times

Summary

This study is collecting blood, urine, and stool samples from 500 children with autoimmune or inflammatory diseases, as well as healthy controls. Researchers will analyze these samples to find molecular patterns that could lead to a tool for better diagnosis and treatment decisions. The goal is to understand why some people get these diseases and why they vary so much.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • hôpital Necker Enfants Malades

    RECRUITING

    Paris, France

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a tool that helps doctors diagnose and choose treatments for autoimmune diseases more accurately.

What could go wrong

This is an observational study, not testing a treatment. It may not directly benefit participants, and the tool may take years to develop or may not work as hoped.

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune enteropathy autoimmune hemolytic anemia autoimmune hepatitis autoimmune lymphoproliferative syndrome autoimmune lymphoproliferative syndrome type 4 autoimmune polyendocrine syndrome type 1 autoimmune thrombocytopenia BENTA disease combined immunodeficiency Epstein-Barr virus-associated lymphoproliferative disorder Evans syndrome hemophagocytic syndrome hereditary hemophagocytic lymphohistiocytosis immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome immunodeficiency 32B inborn error of immunity inflammatory bowel disease juvenile idiopathic arthritis Lymphohistiocytosis, Hemophagocytic Polyendocrinopathies, Autoimmune Primary Immunodeficiency Diseases Purpura, Thrombocytopenic, Idiopathic systemic lupus erythematosus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APECED AUTOIMMUNE ANEMIA AUTOIMMUNE CYTOPENIA AUTOIMMUNE DIABETES AUTOIMMUNE DISEASES AUTOIMMUNE HEPATITIS AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME AUTOIMMUNE RHEUMATOLOGIC DISEASE AUTOIMMUNE THROMBOCYTOPENIA BENTA COMBINED IMMUNODEFICIENCY EBV LYMPHOPROLIFERATION ENTEROPATHY, AUTOIMMUNE HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES IBD IBD IPEX JUVENILE IDIOPATHIC ARTHRITIS PRIMARY IMMUNODEFICIENCY RAS-ASSOCIATED AUTOIMMUNE LEUCOPROLIFERATIVE DISEASE SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC LUPUS ERYTHEMATOSUS